Tag: tumor-agnostic drug development
Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies
By Robert C. Doebele, MD, PhD
Posted: December 11, 2019
Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a...
